<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1905">
  <stage>Registered</stage>
  <submitdate>25/03/2008</submitdate>
  <approvaldate>25/03/2008</approvaldate>
  <nctid>NCT00649298</nctid>
  <trial_identification>
    <studytitle>A Clinical Trial of IntensiVE Dialysis</studytitle>
    <scientifictitle>ACTIVE Dialysis - A Multicentre, Unblinded, Randomised, Controlled Trial to Assess Quality of Life, Clinical Outcomes and Cost Utility for Extended vs Standard Duration of Dialysis in Patients With End Stage Kidney Disease.</scientifictitle>
    <utrn />
    <trialacronym>ACTIVE</trialacronym>
    <secondaryid>GI-R-A001- 09</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Renal Replacement Therapy</healthcondition>
    <healthcondition>Renal Dialysis</healthcondition>
    <healthcondition>End Stage Kidney Disease</healthcondition>
    <healthcondition>End Stage Renal Disease</healthcondition>
    <healthcondition>Uremia</healthcondition>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Kidney disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: surgery - haemodialysis

Experimental: extended hours - 24 or more hours per week of hemodialysis

Active Comparator: standard hours - 18 or less hours per week of hemodialysis


Treatment: surgery: haemodialysis
Comparison of different weekly duration of haemodialysis treatment

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: surgery</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The primary end-point for this study is the difference in the change in quality of life between the two groups from randomisation to the 12 month follow-up as measured by the EQ-5D instrument.</outcome>
      <timepoint>12 months from randomisation</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Survival and cardiovascular analyses</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Quality of life and patient acceptability</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Safety outcomes</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Costs associated with each intervention</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Changes in biochemical and haematological parameters</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Incident or prevalent patients requiring maintenance haemodialysis therapy for ESKD

          2. Aged 18 years or older

          3. Undergoing dialysis for 18 hours per week or less

          4. Suitable for either extended or standard dialysis in the view of the treating
             physician

          5. Agreeable to randomisation</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Life expectancy of less than 6 months

          2. Definite plans to undergo renal transplantation within 12 months of entry to the study

          3. Inability to complete quality of life questionnaire

          4. Concomitant major illness that would limit assessments and followup

          5. High chance that the patient will not adhere to study treatment and follow up in the
             view of the treating physician.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3>The people assessing the outcomes</masking3>
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate />
    <actualstartdate>1/05/2008</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>200</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/10/2014</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>ACT,NSW,QLD,TAS,VIC,WA</recruitmentstate>
    <hospital>The Canberra Hospital - Canberra</hospital>
    <hospital>RPAH/Concord - Sydney</hospital>
    <hospital>Sydney Adventist Hospital - Sydney</hospital>
    <hospital>Liverpool Hospital - Sydney</hospital>
    <hospital>Sydney Dialysis Centre - Sydney</hospital>
    <hospital>Princess Alexandra Hospital - Brisbane</hospital>
    <hospital>Royal Brisbane Hospital - Brisbane</hospital>
    <hospital>Gold Coast Hospital - Gold Coast</hospital>
    <hospital>Nambour General Hospital - Nambour</hospital>
    <hospital>Royal Hobart Hospital - Hobart</hospital>
    <hospital>Austin Hospital - Melbourne</hospital>
    <hospital>Monash Medical Centre - Melbourne</hospital>
    <hospital>Royal Melbourne Hospital - Melbourne</hospital>
    <hospital>Sir Charles Gairdner Hospital - Perth</hospital>
    <postcode> - Canberra</postcode>
    <postcode>2050 - Sydney</postcode>
    <postcode>2076 - Sydney</postcode>
    <postcode> - Sydney</postcode>
    <postcode> - Brisbane</postcode>
    <postcode> - Gold Coast</postcode>
    <postcode> - Nambour</postcode>
    <postcode> - Hobart</postcode>
    <postcode> - Melbourne</postcode>
    <postcode> - Perth</postcode>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>British Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Beijing</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Guangdong</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Hebei</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Henan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Inner Mongolia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Jiangsu</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Jilin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Liaoning</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Shanghai</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Shanxi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Sichuan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>The George Institute</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>National Health and Medical Research Council, Australia</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Baxter Healthcare Corporation</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study will assess clinical outcomes of extended weekly hours of haemodialysis (&gt;= 24
      hours per week) compared with standard hours of haemodialysis (&lt;=18 hours/week) in people
      with ESKD.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00649298</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Vlado Perkovic, MBBS PhD</name>
      <address>The George Institute</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>